Hickman, Richard A. http://orcid.org/0000-0002-8329-6083
Miller, Alexandra M.
Holle, Bridget M.
Jee, Justin
Liu, Si-Yang
Ross, Dara
Yu, Helena
Riely, Gregory J.
Ombres, Christina
Gewirtz, Alexandra N.
Reiner, Anne S.
Nandakumar, Subhiksha
Price, Adam
Kaley, Thomas J.
Graham, Maya S.
Vanderbilt, Chad
Rana, Satshil
Hill, Katherine
Chabot, Kiana
Campos, Carl
Nafa, Khedoudja
Shukla, Neerav
Karajannis, Matthias
Li, Bob
Berger, Michael
Ladanyi, Marc
Pentsova, Elena
Boire, Adrienne
Brannon, A. Rose
Bale, Tejus
Mellinghoff, Ingo K.
Arcila, Maria E.
Funding for this research was provided by:
NINDS (R35 NS105109 03)
National Cancer Institute (P30-CA008748)
Article History
Received: 20 June 2024
Accepted: 3 August 2024
First Online: 17 September 2024
Declarations
:
: IKM reports receiving personal fees (advisory board services) from Agios, Black Diamond Therapeutics, Debiopharm Group, Erasca, Novartis, Prelude Therapeutics, Roche Therapeutics, Servier Pharmaceuticals, Voyager. IKM reports receiving grants from General Electric and Puma Biotechnology. MEA reports consulting for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, Roche, Biocartis, Sanofi. MEA also reports personal fees (advisory roles) for Invivoscribe, Physician Educational Resources (PER), Peerview Institute for medical education, clinical care options, and RMEI medical education. RAH is an employee of Foundation Medicine, Inc., a wholly owned subsidiary of Roche holdings, Inc. and Roche Finance Ltd., and has equity interest in an affiliate of these Roche holdings.